CREB3L1 and neoplasm: The recent development of Nr4a1 agonists that directly bind and activate Nr4a1 may be useful pharmacological tools to increase Creb3l1 expression in tumor cells (Cho et al., 2007; Liu et al., 2010), but our data shows that this would certainly depend on the methylation status of the Creb3l1 promoter.